ImmunityBio Investors Have the Chance to Lead Class Action Lawsuit for Losses

Class Action Lawsuit Opportunity for ImmunityBio Investors

Investors who have faced substantial losses in ImmunityBio, Inc. (NASDAQ: IBRX) recently received important news regarding the opportunity to lead a class action lawsuit against the biotechnology company. The law firm Robbins Geller Rudman & Dowd LLP has announced that eligible investors can seek to be appointed as lead plaintiffs in the case, which includes allegations of securities fraud.

Case Background

The potential class action lawsuit arises from actions and statements made by ImmunityBio and its leadership during the designated class period, which spans from January 19 to March 24, 2026. During this time, the firm claims various misleading statements were made, particularly concerning ImmunityBio's lead product, Anktiva. This immunotherapy product was touted as having the ability to ensure long-term cancer-free outcomes for patients, a claim that has now come under scrutiny.

Key Allegations Raised

The lawsuit articulates serious allegations against both ImmunityBio and its Executive Chairman, Dr. Patrick Soon-Shiong. Specifically, it claims that the company misstated the effectiveness of Anktiva and inaccurately branded it as a cancer vaccine. Moreover, the defendants reportedly exaggerated its potential capabilities when it comes to treating non-muscle invasive bladder cancer (NMIBC).

A pivotal moment occurred on March 24, 2026, when a warning letter from the U.S. Food and Drug Administration (FDA) surfaced, accusing the company of misbranding Anktiva in various promotional materials. This letter not only pointed out violations of the Federal Food, Drug, and Cosmetic Act but also raised concerns about the drug's misleading claims, potentially suggesting it could cure all cancer types. Following the publication of this warning, ImmunityBio's share price dropped significantly—by 21%—indicating investors' immediate reaction to the news.

Who Can Lead the Class Action?

Under the Private Securities Litigation Reform Act of 1995, any individual investor who purchased or acquired ImmunityBio's publicly traded securities during the defined class period can apply to become the lead plaintiff. The lead plaintiff role is generally taken by the individual who has the most financial interest in the outcome of the case and is typical of the class represented. This individual will spearhead the lawsuit and have the power to select a law firm for representation.

It's crucial to note that being appointed as lead plaintiff does not affect an investor's eligibility to benefit from any financial recovery that might occur in the course of the lawsuit. Even those who choose not to take an active lead role may still share in any compensation awarded to the class.

About Robbins Geller Rudman & Dowd LLP

With a reputation as one of the leading law firms in the realm of securities fraud and shareholder rights litigation, Robbins Geller has consistently ranked highly among similar legal entities. In fact, they recouped over $916 million for investors in 2025 alone, further establishing their position as a heavyweight in investor protection. Over the last several years, their efforts have yielded approximately $8.4 billion in recoveries for investors, showcasing their expertise and dedication to protecting shareholders’ rights.

For ImmunityBio investors looking to participate in the class action lawsuit, detailed information and assistance can be obtained directly through Robbins Geller's website. Potential claimants are encouraged to act swiftly, as the deadline to file for lead plaintiff status is May 26, 2026.

For further inquiries, investors can contact attorneys Ken Dolitsky or Michael Albert at Robbins Geller directly at 800-449-4900 or via email. As news develops, keeping abreast of changes will be crucial for all affected investors.

As the situation unfolds, the investment community watches closely, with many hoping for a resolution that provides just compensation for the alleged losses incurred from ImmunityBio's controversial strategies and communications during the pivotal class period.